학술논문
Biomarkers of disease progression in people with psoriasis:a scoping review
Document Type
Electronic Resource
Author
Source
Ramessur , R , Corbett , M , Marshall , D , Acencio , M L , Barbosa , I A , Dand , N , Di Meglio , P , Haddad , S , Jensen , A H M , Koopmann , W , Mahil , S K , Ostaszewski , M , Rahmatulla , S , Rastrick , J , Saklatvala , J , Weidinger , S , Wright , K , Eyerich , K , Ndlovu , M , Barker , J N , Skov , L , Conrad , C , Smith , C H & BIOMAP consortium 2022 , ' Biomarkers of disease progression in people with psoriasis : a scoping review ' , British Journal of Dermatology , vol. 187 , no. 4 , pp. 481-493 .
Subject
Language
Abstract
Background: Identification of those at risk of more severe psoriasis and/or associated morbidities offers opportunity for early intervention, reduced disease burden and more cost-effective healthcare. Prognostic biomarkers of disease progression have thus been the focus of intense research, but none are part of routine practice. Objectives: To identify and catalogue candidate biomarkers of disease progression in psoriasis for the translational research community. Methods: A systematic search of CENTRAL, Embase, LILACS and MEDLINE was performed for relevant articles published between 1990 and December 2021. Eligibility criteria were studies involving patients with psoriasis (any age, n ≥ 50) reporting biomarkers associated with disease progression. The main outcomes were any measure of skin severity or any prespecified psoriasis comorbidity. Data were extracted by one reviewer and checked by a second; studies meeting minimal quality criteria (longitudinal design and/or use of methods to control for confounding) were formally assessed for bias. Candidate biomarkers were identified by an expert multistakeholder group using a majority voting consensus exercise, and mapped to relevant cellular and molecular pathways. Results: Of 181 included studies, most investigated genomic or proteomic biomarkers associated with disease severity (n = 145) or psoriatic arthritis (n = 30). Methodological and reporting limitations compromised interpretation of findings, most notably a lack of longitudinal studies, and inadequate control for key prognostic factors. The following candidate biomarkers with future potential utility were identified for predicting disease severity: LCE3D, interleukin (IL)23R, IL23A, NFKBIL1 loci, HLA-C*06:02 (genomic), IL-17A, IgG aHDL, GlycA, I-FABP and kallikrein 8 (proteomic), tyramine (metabolomic); psoriatic arthritis: HLA-C*06:02, HLA-B*27, HLA-B*38, HLA-B*08, and variation at the IL23R and IL13 loci (genomic); IL-17A, CXCL10, Mac-2 binding protein, i